Trials / Completed
CompletedNCT00299377
Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Randomized Comparison of Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- University of Leipzig · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved epicardial flow, perfusion, reduction of no-reflow, reduction in infarct size and subsequently better outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abciximab i.v. | |
| DRUG | Abciximab i.c. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-11-01
- Completion
- 2008-02-01
- First posted
- 2006-03-06
- Last updated
- 2008-07-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00299377. Inclusion in this directory is not an endorsement.